Document:

Amendment No. 1 to the License and Supply Agreement

 Exhibit 10.31.1 
 The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and
Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***. 
 AMENDMENT NO. 1 TO LICENSE AND SUPPLY
AGREEMENT 
 This Amendment No. 1 to that certain License and Supply Agreement (this “Amendment”) is entered into as of March 28,
2008, by and among Novartis AG, Novartis Consumer Health, Inc. (collectively, “Novartis”) and Endo Pharmaceuticals Inc. (“Endo”). 
 WHEREAS, the Parties entered into a License and Supply Agreement on March 4, 2008 (the “License Agreement”); and 
 WHEREAS, the
terms and conditions in the License Agreement continue to be in full force and effect between the Parties except as modified as set forth below; 
 NOW
THEREFORE, in consideration of the premises and covenants herein contained the Parties agree as follows: 
 1. The Terms used but not defined herein shall
have the meanings set forth in the License Agreement. 
 2. Exclusive Negotiating Period for Line Extensions. Novartis hereby agrees that the ninety
(90) day exclusive negotiation period for a license to Line Extensions referred to in Section 10.1(b) of the License Agreement will not commence until the delivery to Endo of both Novartis’ proposal relating thereto and information
reasonably necessary for Endo to evaluate such opportunity. 
 3. Manufacture and Supply. 
 (a) The Parties hereby agree that, effective as of the Execution Date, Novartis AG shall be substituted for Novartis as a party to Sections 5.1-5.11 of
the License Agreement. 
 (b) During the period from the Execution Date through March 31, 2008 (“Q1 2008”), all purchases of
Licensed Product under Section 5 of the License Agreement shall be made by Endo, and for all periods thereafter during the Term of the License Agreement until the Parties otherwise agree, all purchases of Licensed Product under Section 5
of the License Agreement shall be made by Endo Pharma Ireland Limited or another subsidiary identified by Endo to Novartis in writing (any such party, “Endo Sub”). For purposes thereof, Endo Sub is hereby made a party to Section 5 of
the License Agreement and shall have all the rights and obligations of Endo with respect thereto. 

 (c) Upon execution of this Amendment, Endo shall issue purchase orders for the Licensed Product listed on
Annex A to this Amendment. Upon Novartis’s acceptance and invoicing of such purchase orders and only if such acceptance and invoicing occurs prior to March 31, 2008, all ownership, title and risk of loss of such Licensed Product
shall belong to Endo prior to March 31, 2008, it being understood that Novartis attributes sales to a reporting period under the Medicaid Drug Rebate Program, as codified at 42 U.S.C. § 1396r-8, based on the invoice date of the
sale. 
 (d) The Parties hereby agree that Section 5.4(a) and (e) of the License Agreement shall not apply until July 1, 2008
and that Section 5.13 of the License Agreement shall not apply until October 31, 2008. 
 4. Price Reporting and Related Government
Contracting. 
 (a) For Q1 2008, with respect to the Licensed Product Novartis shall be solely responsible for (1) calculating and
reporting prices for Licensed Product under the Medicaid Drug Rebate Program, as codified at 42 U.S.C. § 1396r-8, including making all decisions with respect thereto, in its discretion, and (2) providing any related certifications to
applicable Government Authorities, and (3) reporting and compliance with all state law requirements regarding price disclosure and reporting. Novartis shall inform Endo of all decisions and actions taken pursuant to the prior sentence prior to
taking such decisions and/or actions. For Q2 2008 and all periods thereafter during the Term of the License Agreement, with respect to the Licensed Product Endo shall be solely responsible for (1) calculating and reporting prices for Licensed
Product under the Medicaid Drug Rebate Program, including making all decisions with respect thereto, in its discretion, and (2) providing any related certifications to applicable Government Authorities, and (3) reporting and compliance
with all state law requirements regarding price disclosure and reporting. Endo’s responsibilities as of Q2 2008 shall apply to Licensed Product without regard to whether Licensed Product bears the National Drug Code of Novartis or Endo. Neither
Party shall have any responsibility or liability for decisions made or actions taken by the other Party under this paragraph. *** Each Party shall supply to the other Party with any information reasonably requested by the other Party that the other
Party needs to perform its responsibilities under this paragraph. 
 (b) CMS DDR Price Reporting. The applicable Novartis
representative will be responsible for establishing within the Centers for Medicare & Medicaid Services (“CMS”) database the Licensed Product bearing the Novartis labeler code 0067. Effective with the April 2008 monthly Average
Manufacturer’s Price (“AMP”) filing and thereafter, Novartis will transfer reporting responsibility to the applicable Endo representative via the CMS Drug Data Reporting (“DDR”) system for the Licensed Product. Endo will be
responsible for establishing within the CMS DDR the Licensed Product bearing an Endo labeler code. 
  

 2 

 (c) Public Health Service (PHS). Endo shall have responsibility for all aspects of PHS
contract pricing for the Licensed Product. 
 (d) Federal Supply Schedule (FSS). Endo shall have responsibility for all aspects
of FSS pricing and non-Federal Average Manufacturer Price reporting for the Licensed Product. Immediately following execution of this Amendment (and no event later than three days following), Novartis will provide to Endo all correspondence related
to the Licensed Product occurring between Novartis and any of its affiliates and the Veterans Administration office (VA). 
 (e) Pricing
Compendia. Endo will be responsible for notifying the various pricing Compendia of the availability of Licensed Product and the Wholesale Acquisition Cost (“WAC”) pricing as established by Endo for the Licensed Product. The
applicable Novartis representative will be included in such notification and will communicate to the Compendia as necessary in order to grant Endo the exclusive right to report and update the information for the Licensed Product. 
 (f) The provisions of Sections 2.2, 15.1 and 20 of the License Agreement shall apply to this Amendment. For the purposes of this paragraph (f), the
provisions of this Amendment shall be considered covenants and agreements of, or representations and warranties made by, the Parties in the License Agreement. 
 (g) Information provided by one Party to the other Party under this paragraph 3 shall constitute “Confidential Information,” as defined in section 1.26 of the License Agreement and the provisions of
Section 14 of the License Agreement shall apply to each Party’s treatment of that information. 
 (h) Notwithstanding Endo’s
assumption of all responsibilities relating to calculation and reporting of prices for Licensed Product under the Medicaid Drug Rebate Program effective April 1, 2008, Novartis shall retain the responsibility for processing and paying rebate
claims relating to Licensed Product bearing the Novartis labeler code 0067 submitted by the States under the Medicaid Drug Rebate Program for all periods during the Term of the License Agreement. On a quarterly basis Endo shall reimburse Novartis
for Medicaid rebate claims paid by Novartis relating to Licensed Product. Endo shall pay Novartis within sixty (60) days of Endo’s receipt of an itemization of these Medicaid claims and supporting documentation, including utilization
reports. Novartis shall be solely responsible for any interest incurred as a result of late payments to the States. Endo shall have the right to initiate a dispute with a State for reasonable cause, and Novartis shall cooperate with any such actions
taken by Endo. 
  

 3 

 IN WITNESS WHEREOF, NOVARTIS AG, NOVARTIS and ENDO have caused this Amendment to be executed by their duly authorized
representatives as of the day and year first above written. 
  

			
	ENDO PHARMACEUTICALS INC.
		
	By	 	/s/ CHARLES A. ROWLAND, JR.
		 	     Name: Charles A. Rowland, Jr.
		 	     Title: EVP, CFO & Treasurer

  

			
	NOVARTIS AG
		
	By	 	/s/ PAUL DAVID BURNS
		 	     Name: Paul David Burns
		 	     Title:
		
	By	 	/s/ PETER RUPPRECHT
		 	     Name: Peter Rupprecht
		 	     Title:

  

			
	NOVARTIS CONSUMER HEALTH, INC.
		
	By	 	/s/ JOHN COWLES
		 	     Name: John Cowles
		 	     Title: SVP, GM NCH OTC

  

 4 

 Annex A to Amendment No. 1 dated March 28, 2008 
 Voltaren 100g Inventory March 24, 2008 
  

							
	 Batch
	  	 Quantity
	  	 Location
	  	 SAP PO#

	***	  	***	  	***	  	***

  

 5First Amendment to Lease Agreement

 Exhibit 10.40.1 
 FIRST AMENDMENT TO LEASE 
 THIS IS AN AMENDMENT (“Amendment”) made this 3rd day of March,
2008, between PAINTERS’ CROSSING THREE ASSOCIATES, L.P. (“Landlord”) and ENDO PHARMACEUTICALS INC. (“Tenant”). 
 WITNESSETH: 
 WHEREAS, the parties entered into the Lease Agreement dated January 19, 2007
(“Original Lease”) for approximately 48,600 +/- square feet of space known as Painters’ Crossing Three Building (“Demised Premises”), located at 300 Endo Boulevard, Painters’ Crossing Office Campus (“Campus”),
Chadds Ford, Delaware County, Commonwealth of Pennsylvania; and 
 WHEREAS, the parties wish to confirm the Commencement Date of the Lease
and, subject to the terms and conditions of the Lease and the terms and conditions set forth herein. 
 NOW, THEREFORE, the parties hereto,
in consideration of the mutual promises and covenants contained herein and intending to be legally bound hereby, agree as follows: 
 1. The
“Commencement Date” of the Lease is hereby confirmed to be April 1, 2008. 
 2. The “Term” of the
Lease shall be for ten (10) years beginning April 1, 2008 and ending March 31, 2018. Tenant has no options to purchase the Demised Premises and no option to renew the Lease. 
 3. Early Occupancy. 
 If the
Demised Premises are ready for occupancy prior to the Commencement Date, Tenant may occupy the Demised Premises under the following terms and conditions: 
         a. Rent shall not be due and payable until April 1, 2008 except Tenant shall assume all costs for utilities within and to the Demised Premises upon the date of
Early Occupancy; and 
         b. The first month’s rent shall be paid prior to occupancy; and

         c. All terms and provisions of the Lease shall be applicable to Tenant’s occupancy
during the period prior to the Commencement Date specified in the Lease; and 
         d. Landlord
shall be in receipt of a signed First Amendment to Lease and a copy of Tenant’s insurance certificate for the Demised Premises. 
  

 IN WITNESS WHEREOF, the parties have hereunto duly executed this Amendment to the Lease the day and year
first above written. 
  

									
	 SEALED AND DELIVERED IN THE PRESENCE OF:
	  		  		 	
				
		 		  		  	LANDLORD:
				
		 		  		  	PAINTERS’ CROSSING THREE ASSOCIATES, L.P.
		 		  		  	By:	 	Henderson P.O.C. Three, LLC, General Partner
					
	WITNESS:	 	/s/ John B. Condon	  		  	By:	 	/s/ Wilbur C. Henderson
		 		  		  		 	      Wilbur C. Henderson, Manager
				
		 		  		  	TENANT:
				
		 		  		  	ENDO PHARMACEUTICALS INC.
					
	ATTEST:	 	/s/ Caroline B. Manogue	  		  	By:	 	/s/ Nancy J. Wysenski
		 	Name: Caroline B. Manogue	  		  		 	      Nancy J. Wysenski
		 	Title:   Executive Vice President	  		  		 	      COO
		 	            Chief Legal Officer and Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]